Insider buying last 90 days
No open-market insider purchases were filed for RDY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RDY insider filing, plotted on the chart in Gekko.Open RDY in Gekko
Dr. Reddy's Laboratories (RDY) Stock Analysis & Forecast
Sep 28 close
$12.51+0.26 (+2.1%)
Gekko Brief
AI summaryDr. Reddy's shares edged up modestly on Friday even as the stock traded well below its 52-week high, underperforming a broader market gain. Management joined an in-person Nomura investor conference in Hyderabad on 25 September, and the company's trading window has since closed ahead of its 23 October results meeting, where the board will review the quarter ending 30 September 2026. Separately, Pomerantz LLP has announced it is investigating claims on behalf of Dr. Reddy's investors, and a fund disclosed a new position in the stock during the second quarter.
RDY closed at $12.51, up 2.1%, sitting between its 50-day average of $12.10 and its 200-day average of $13.32. The GekkoIndex reads 51.2, placing the stock in the Neutral zone, down 2.9 over the past five sessions. Gekko Fair Value stands at $12.88, putting price about 2.9% below that mark.
The next earnings date falls on 23 October, before the open, 24 days out and inside a typical 20-trading-day holding window; the prior report on 21 July saw a -9.2% reaction on a miss versus estimate. Seasonality over the past 5 years shows a -0.9% average return across the next 20 trading days from this point, with gains in 2 of those years. No insider, Congress or unusual options activity appears in the current windows. Analyst consensus target sits at $13.35, implying 6.7% upside.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Dr. Reddy's Laboratories price vs fair value
Close $12.51200-day averageGekko Fair Value $12.88
Dr. Reddy's Laboratories quick facts
- Market cap
- $10.42B
- P/E ratio
- 30
- Forward P/E
- 27
- EPS, TTM
- $0.41
- Revenue, TTM
- $331.2B
- Profit margin
- 10%
- Dividend yield
- 0.68%
- Beta
- 0.24
- Volume
- 4.03M avg 2.74M
- 1-year return
- −11.7%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.2%
- 50-day average
- $12.10
- 200-day average
- $13.32
- Next earnings
- Oct 23 before open
- Shares outstanding
- 833.0M
Dr. Reddy's Laboratories swing-trade checklist
Dr. Reddy's Laboratories scores 0 supportive, 3 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive3 mixed2 headwinds
- Trendmixed
Averages disagree
Close $12.51 sits between the 50-day ($12.10) and 200-day ($13.32) averages, or the averages disagree.
See the chart - GekkoIndexmixed
51.2, Neutral
Reading 51.2 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
2.9% below
Price is within 5% of Gekko Fair Value (2.9% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Oct 23, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.9% on average
From this point in the calendar, the next 20 trading days averaged −0.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Dr. Reddy's Laboratories stock chart and price history
Dr. Reddy's Laboratories closed at $12.51 on Sep 28, 2026, −11.7% over the past year, inside a 52-week range of $11.36 to $15.67.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.9%
- 3 months
- −15.8%
- 6 months
- −7.2%
- 1 year
- −11.7%
The full RDY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RDY in Gekko
Follow Dr. Reddy's Laboratories through every session
Put RDY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RDY in GekkoFree for 7 days. No credit card required.
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories operates as a full-scale pharmaceutical business with reach across many countries. It makes and sells both branded and generic medicines, covering areas such as digestive health, heart conditions, diabetes, skin treatments, cancer, breathing disorders, dental care, and kidney and urinary conditions. Its generic drugs are built to match the therapeutic effect of their branded counterparts, and this side of the business also includes biologic products.
Beyond finished medicines, the company produces active pharmaceutical ingredients and related chemical components used as inputs for drug manufacturing, along with contract research work and custom-made ingredients and steroids for outside clients. It also has a unit focused on developing new proprietary drug formulations, and another working on treatments for cancer and inflammatory diseases. A collaboration with Curis, Inc. supports work on small molecule compounds aimed at immuno-oncology and precision oncology.
Dr. Reddy's was established in 1984 and is headquartered in Hyderabad, India. Its shares trade under the ticker RDY.
- Sector
- Health technology
- Website
- drreddys.com
Dr. Reddy's Laboratories GekkoIndex: the smart money zone
Dr. Reddy's Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.2, in the Neutral zone, down 2.9 points over five sessions.
51.2Neutral
Down 2.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +1.9% | +4.1% | ||
| Accumulation | 266 | +0.1% | −0.1% | ||
| Neutral (current zone) | 300 | −0.4% | −0.9% | ||
| Distribution | 20 | −0.3% | −3.0% | ||
| Selling | 2 | Too few readings yet | |||
Average RDY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RDY price, zone by zone.Track RDY in Gekko
Is Dr. Reddy's Laboratories stock overvalued? Gekko Fair Value
Dr. Reddy's Laboratories trades 2.9% below Gekko Fair Value of $12.88, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Dr. Reddy's Laboratories shares are worth, recalculated every trading day.
$12.88
Gekko Fair Value, Sep 26, 2026
2.9% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open RDY in Gekko
Dr. Reddy's Laboratories insider and Congress trading
No open-market insider purchases were filed for Dr. Reddy's Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RDY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RDY, plotted on the chart in Gekko.Open RDY in Gekko
Dr. Reddy's Laboratories earnings: next date and track record
Dr. Reddy's Laboratories reports on Oct 23, 2026, before the open (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 23, 2026
Expected before the open, 24 days away
- EPS estimate
- $0.10
- Revenue estimate
- $843.5M
4 of 8reports beat the EPS estimate
±3.9%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 21, 2026 AI summary
- What they said
- Dr. Reddy's Q1 FY2027 reported consolidated revenue of INR 8,071 crores ($853M), down 5.6% YoY but up 7.4% sequentially. EBITDA margin was 12.5%, impacted by lower lenalidomide revenues and a INR 240 crore semaglutide API-related provision. Gross margin declined 1,039 bps YoY to 46.5%. Excluding the semaglutide provision, EBITDA margin was 15.4%. Base business ex-lenalidomide delivered healthy double-digit growth across key geographies.
- Guidance
- Management did not provide explicit forward-looking revenue or earnings targets in this excerpt. Strategic focus remains on new product launches across geographies and branded business investments, with semaglutide API challenges representing a near-term headwind.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 21, 2026 | $0.06 est $0.17 | $835.7M est $850.6M | −9.2% |
| May 11, 2026 | $0.00 est $0.16 | $785.9M est $886.6M | −5.8% |
| Jan 20, 2026 | $0.16 est $0.16 | $951.6M est $927.7M | +2.8% |
| Oct 24, 2025 | $0.20 est $18.31 | $1.00B est $979.8M | −1.0% |
| Jul 23, 2025 | $17.02 est $0.21 | $988.9M est $1.01B | +2.1% |
| May 9, 2025 | $19.11 est $17.13 | $996.2M est $978.2M | +5.7% |
| Jan 29, 2025 | $16.94 est $16.15 | $969.6M est $975.7M | +2.1% |
| Nov 5, 2024 | $15.83 est $17.69 | — | +2.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Dr. Reddy's Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for Dr. Reddy's Laboratories is $13.35, +6.7% from the last close.
$13.35consensus 12-month target, +6.7% from the last close
−0.9%average 20-day move after past Neutral readings
−0.9%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Dr. Reddy's Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Dr. Reddy's Laboratories averaged −0.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.1% | 3 of 5 |
| Next 10 trading days | −0.3% | 1 of 5 |
| Next 15 trading days | +0.2% | 1 of 5 |
| Next 20 trading days | −0.9% | 2 of 5 |
| Next 30 trading days | −0.2% | 1 of 5 |
For scale, RDY’s typical 20-trading-day move in either direction is about 4.2%.
Dr. Reddy's Laboratories market cap and key statistics
Dr. Reddy's Laboratories’s market cap is $10.42B, with a P/E ratio of 30 and revenue of $331.2B over the last twelve months.
Valuation
- Market cap
- $10.42B
- P/E ratio
- 30
- Forward P/E
- 27
- EPS, TTM
- $0.41
- Gekko Fair Value
- $12.88
Trading
- Volume
- 4.03M
- Avg volume, 20 days
- 2.74M
- 52-week high
- $15.67
- 52-week low
- $11.36
- Shares outstanding
- 833.0M
Financials
- Revenue, TTM
- $331.2B
- Profit margin
- 10%
- Return on equity
- 8.8%
- Quarterly earnings growth, YoY
- −68.7%
Risk and income
- Beta
- 0.24
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.2%
- Dividend yield
- 0.68%
Dr. Reddy's Laboratories stock news this week
Coverage of Dr. Reddy's Laboratories this week reads neutral: 1 positive, 3 neutral and 1 negative headlines.
- Dr. Reddy's Laboratories advances Friday, underperforms marketMarketWatch, Sep 25
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYPRNewsWire, Sep 24
- Nykredit A S Takes Position in Dr. Reddy's Laboratories Ltd $RDYMarketBeat, Sep 23
- Trading window closes at Dr. Reddy’s (NYSE: RDY) before Oct. 23 results meetingStock Titan, Sep 23
- In-person Nomura investor meet for Dr. Reddy’s (NYSE: RDY) on Sep 25Stock Titan, Sep 22
- Dr. Reddy’s Laboratories Ltd (RDY) Stock Analysis: A 9.6% Potential Upside in the Healthcare SectorDirectorsTalk Interviews, Sep 21
Dr. Reddy's Laboratories stock FAQ
What is Dr. Reddy's Laboratories’s market cap?
Dr. Reddy's Laboratories’s market cap is $10.42B at the Sep 28, 2026 close of $12.51, with 833.0M shares outstanding. The shares trade on a P/E ratio of 30.
What is the Dr. Reddy's Laboratories stock forecast?
The consensus analyst 12-month price target for Dr. Reddy's Laboratories is $13.35, +6.7% from the last close. Gekko doesn’t publish price predictions of its own.
Is Dr. Reddy's Laboratories stock overvalued or undervalued?
On Gekko’s estimate Dr. Reddy's Laboratories is about fair value: the Sep 28, 2026 close of $12.51 is 2.9% below Gekko Fair Value of $12.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Dr. Reddy's Laboratories report earnings next?
Dr. Reddy's Laboratories is expected to report on Oct 23, 2026, before the market opens (24 days away). Analysts expect earnings of $0.10 per share on revenue of $843.5M. Dr. Reddy's Laboratories beat the earnings estimate in 4 of its last 8 reports, moving 3.9% on average across the report.
What is Dr. Reddy's Laboratories’s 52-week high and low?
Dr. Reddy's Laboratories’s 52-week high is $15.67 and its 52-week low is $11.36; it closed at $12.51 on Sep 28, 2026, −11.7% over the past year. Over the last five years the shares peaked at $16.89 on Aug 9, 2024.
Is Dr. Reddy's Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 5 items with data read as supportive, 3 as mixed (trend, gekkoindex and fair value) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Dr. Reddy's Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.